H.C. Wainwright raised the firm’s price target on Immix Biopharma (IMMX) to $15 from $12 and keeps a Buy rating on the shares following the Q4 results. The firm expects results from NEXICART-2 and a regulatory filing in 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMX:
- Immix Biopharma Amends ATM Offering to Raise Capital
- Immix Biopharma initiated with an Overweight at Morgan Stanley
- Immix Biopharma initiated with an Outperform at Citizens
- Immix Biopharma initiated with an Outperform at Mizuho
- Immix Biopharma receives FDA breakthrough therapy designation for NXC-201